Cbp France Company Overview, Contact Details & Competitors

Q: What is Cbp France's official website and social media links?

Cbp France's official website is kereisfrance.com. Cbp France has social profiles on LinkedIn.

Q: How many employees does Cbp France have currently?

Cbp France has approximately 920 employees.

Q: What technology does Cbp France use?

Cbp France's tech stack includes TikTok, Swiper, WordPress, Qlik Sense, RSS.

Insights

Gathering insights about Cbp France…

Similar companies to Cbp France

Cbp France Tech Stack

Cbp France uses 8 technology products and services including WordPress, Webpack, jQuery, and more. Explore Cbp France's tech stack below.

WordPress
Content Management System
Webpack
Development
jQuery
Javascript Libraries
Genesys Cloud
Marketing Automation
JavaScript
Programming Languages
Python
Programming Languages
Kibana
Visualisation Software
HTTP/3
Web & Portal Technology

Media & News

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
First patient in Cohort B achieved CR after 2nd dose of TCB008 EDINBURGH, Scotland , June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008. The response was achieved after the patient's second dose of 250,000,000 gamma delta t-cells, two weeks after treatment began, in total the patient received approximately 500,000,000 gamma delta t-cells over two weeks.
Jun 11, 2025 | www.prnewswire.com
TCBP Announces Transition from Nasdaq to OTC Markets
EDINBURGH, Scotland , March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share.
Mar 21, 2025 | www.prnewswire.com
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
The company is expected to reduce core operational burn by 55% when compared to 2024 EDINBURGH, Scotland , March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and other cell therapy production technologies.
Mar 18, 2025 | www.prnewswire.com
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
FDA-approved product in a multi-billion-dollar market Revenue generation projected in 2025 EDINBURGH, Scotland , March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension. The acquisition candidate has an FDA-approved once-per-day drop to decrease intraocular pressure, a pipeline of development stage assets in ophthalmology indications, and is led by a seasoned management team.
Mar 05, 2025 | www.prnewswire.com
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27 th at 1:10 pm CET at the 18th Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics. The forum will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel.
Feb 20, 2025 | www.prnewswire.com
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland , Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. The available data show a favorable safety and efficacy response in Cohort A patients, patients with relapse or refractory AML.
Feb 13, 2025 | www.prnewswire.com
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
First Cohort B patient received 4 doses (approx. 819 million Gamma Delta T-cells) Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland , Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment.
Feb 10, 2025 | www.prnewswire.com

Cbp France's Email Address Formats

Cbp France uses at least 2 format(s):

Cbp France Email Formats	Example	Percentage
First.Last@cbp-group.com	John.Doe@cbp-group.com	98%
Last.First@cbp-group.com	Doe.John@cbp-group.com	2%
First.Last@kereisfrance.com	John.Doe@kereisfrance.com	100%

Frequently Asked Questions

What is Cbp France's stock symbol?

Cbp France is a publicly traded company; the company's stock symbol is TCBP.

What is Cbp France's official website and social media links?

Cbp France's official website is kereisfrance.com and has social profiles on LinkedIn.

What is Cbp France's SIC code NAICS code?

Cbp France's SIC code is 7299 - Miscellaneous Personal Services, Not Elsewhere Classified NAICS code is 524 - Insurance Carriers and Related Activities.

How many employees does Cbp France have currently?

As of December 2025, Cbp France has approximately 920 employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Ceo/Operator: S. T.Chief Of Staff National Vetting Center: D. V.Membre Du Cd De Cbp Quilvest: D. K.. Explore Cbp France's employee directory with LeadIQ.

What industry does Cbp France belong to?

Cbp France operates in the Insurance industry.

What technology does Cbp France use?

Cbp France's tech stack includes WordPressWebpackjQueryGenesys CloudJavaScriptPythonKibanaHTTP/3.

What is Cbp France's email format?

Cbp France's email format typically follows the pattern of First.Last@cbp-group.com. Find more Cbp France email formats with LeadIQ.

When was Cbp France founded?

Cbp France was founded in 1991.

Insights

Similar companies to Cbp France

Credibly

Lendio

Bluevine

Rapid Finance

Behalf

Fora Financial

National Funding

OnDeck

CAN Capital

Fundbox

Cbp France Tech Stack

Media & News

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TCBP Announces Transition from Nasdaq to OTC Markets

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

Cbp France's Email Address Formats

Frequently Asked Questions

What is Cbp France's stock symbol?

What is Cbp France's official website and social media links?

What is Cbp France's SIC code NAICS code?

How many employees does Cbp France have currently?

What industry does Cbp France belong to?

What technology does Cbp France use?

What is Cbp France's email format?

When was Cbp France founded?

Cbp France

Company Overview

Media & News

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TCBP Announces Transition from Nasdaq to OTC Markets

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?